SecSonar.com

Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Cartesian Therapeutics, Inc. (RNAC) is a Biotechnology company based in US with a market capitalization of $212.4M. Revenue declined 92.8% year-over-year and free cash flow was negative at -$79.4M. This page tracks RNAC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 66 employees · IPO Jun 22, 2016

Valuation

Valuation & price

$7.38 · as of May 17, 2026 · -46.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$13.77$9.80$5.84Jul 25Dec 25Jul 26Jul 7, 25$10.77Jul 9, 25$13.77Jul 11, 25$13.32Jul 15, 25$13.58Jul 17, 25$12.53Jul 21, 25$12.05Jul 23, 25$13.39Jul 25, 25$13.33Jul 29, 25$13.40Jul 31, 25$12.81Aug 4, 25$12.48Aug 6, 25$11.28Aug 11, 25$11.10Aug 13, 25$11.71Aug 15, 25$11.33Aug 19, 25$10.85Aug 21, 25$10.96Aug 25, 25$11.25Aug 27, 25$10.63Aug 29, 25$10.05Sep 3, 25$10.25Sep 5, 25$10.64Sep 9, 25$10.09Sep 11, 25$9.96Sep 16, 25$9.60Sep 18, 25$10.31Sep 22, 25$10.04Sep 24, 25$10.07Sep 26, 25$9.26Sep 30, 25$10.22Oct 2, 25$10.34Oct 6, 25$10.00Oct 8, 25$10.23Oct 10, 25$9.32Oct 14, 25$9.42Oct 16, 25$9.42Oct 21, 25$9.28Oct 23, 25$9.00Oct 27, 25$8.85Oct 29, 25$8.20Oct 31, 25$8.17Nov 4, 25$7.71Nov 6, 25$7.55Nov 10, 25$7.24Nov 12, 25$7.58Nov 14, 25$7.46Nov 18, 25$7.62Nov 20, 25$7.15Nov 25, 25$7.32Nov 28, 25$7.49Dec 2, 25$6.71Dec 4, 25$6.90Dec 8, 25$6.72Dec 10, 25$7.85Dec 12, 25$8.52Dec 16, 25$8.29Dec 18, 25$7.36Dec 22, 25$6.72Dec 24, 25$6.76Dec 29, 25$6.47Jan 2, 26$6.76Jan 6, 26$7.04Jan 8, 26$8.12Jan 12, 26$7.27Jan 14, 26$7.64Jan 16, 26$7.42Jan 21, 26$7.64Jan 23, 26$7.64Jan 27, 26$7.40Jan 29, 26$6.98Feb 2, 26$6.79Feb 4, 26$6.84Feb 9, 26$6.50Feb 11, 26$6.40Feb 13, 26$6.52Feb 18, 26$6.64Feb 20, 26$6.93Feb 24, 26$7.55Feb 26, 26$8.35Mar 2, 26$7.60Mar 4, 26$7.87Mar 6, 26$6.85Mar 10, 26$8.55Mar 12, 26$8.12Mar 17, 26$7.18Mar 19, 26$6.57Mar 23, 26$6.60Mar 25, 26$6.25Mar 27, 26$5.85Mar 31, 26$6.15Apr 2, 26$6.26Apr 7, 26$6.28Apr 9, 26$6.18Apr 13, 26$5.93Apr 15, 26$5.99Apr 17, 26$7.04Apr 22, 26$6.89Apr 24, 26$6.75Apr 28, 26$6.80Apr 30, 26$6.22May 4, 26$6.93May 6, 26$8.34May 8, 26$8.65May 12, 26$8.70May 14, 26$8.27May 18, 26$6.89May 20, 26$6.52May 22, 26$6.75May 28, 26$7.21Jun 1, 26$6.92Jun 3, 26$6.27Jun 5, 26$5.84Jun 9, 26$6.85Jun 11, 26$8.06Jun 15, 26$8.60Jun 17, 26$9.88Jun 22, 26$9.95Jun 24, 26$9.64Jun 26, 26$9.42Jul 2, 26$10.59
$5.8452-week range$13.77
Loading valuation history…

Fundamentals

Key fundamentals

$212.4M

Market cap

-92.8%

Revenue growth (YoY)

100.0%

Gross margin

-$79.4M

Free cash flow (USD)

-$112.5M

Net debt

Net cash position

0.3%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$8.1MFY 2017$207.0KFY 2018$903.0KFY 2019$6.7MFY 2020$16.6MFY 2021$85.1MFY 2022$110.8MFY 2023$26.0MFY 2024$38.9MFY 2025$2.8M
$8.1M$2.8M

Free cash flow by year

2016 → 2025

FY 2016$-20.3MFY 2017$-52.8MFY 2018$-60.0MFY 2019$-51.5MFY 2020$34.1MFY 2021$-61.5MFY 2022$-32.8MFY 2023$-51.4MFY 2024$-32.8MFY 2025$-79.4M
-$20.3M-$79.4M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 202298.2%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 17, 2026Filing
  • 8-K eventStrategic Licensing AgreementJun 9, 2026Filing
  • 8-K eventLoan Agreement ExecutedMay 26, 2026Filing
  • 8-K eventEarnings ReleaseApr 30, 2026Filing
  • Quarterly report10-Q FiledApr 30, 2026Filing

Questions

Frequently asked questions

What is Cartesian Therapeutics, Inc.'s market cap?

Cartesian Therapeutics, Inc. (RNAC) has a market capitalization of $212.4M.

What is RNAC's P/E ratio?

A meaningful P/E ratio is not available for RNAC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying RNAC stock?

SEC Form 4 filings show no open-market insider buys at Cartesian Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

NBP

NovaBridge Biosciences

$213.2M

PRLD

Prelude Therapeutics Incorporated

$218.6M

IPSC

Century Therapeutics, Inc.

$205.2M

HUMA

Humacyte, Inc.

$222.6M

YDES

YD Bio Limited Ordinary Shares

$223.1M

SLGL

Sol-Gel Technologies Ltd.

$225.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.